Agios Opens Doors To Other Investors, Expands Into Genetic Disorders
This article was originally published in The Pink Sheet Daily
Executive Summary
Agios brings in a $78 million in financing from both previous venture investors and new public investor funds, as it embarks on research of rare diseases caused by an inborn error of metabolism.